MX2009010701A - Metodos para inhibir la union de endosialina a ligandos. - Google Patents

Metodos para inhibir la union de endosialina a ligandos.

Info

Publication number
MX2009010701A
MX2009010701A MX2009010701A MX2009010701A MX2009010701A MX 2009010701 A MX2009010701 A MX 2009010701A MX 2009010701 A MX2009010701 A MX 2009010701A MX 2009010701 A MX2009010701 A MX 2009010701A MX 2009010701 A MX2009010701 A MX 2009010701A
Authority
MX
Mexico
Prior art keywords
ligands
endosialin
inhibiting
binding
methods
Prior art date
Application number
MX2009010701A
Other languages
English (en)
Inventor
Yuhong Zhou
Brian E Tomkowicz
Luigi Grasso
Philip M Sass
Nicholas C Nicolaides
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of MX2009010701A publication Critical patent/MX2009010701A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención proporciona métodos para inhibir la interacción de endosialina con ligandos de endosialina. La inhibición se realiza al bloquear la interacción de endosialina expresada en superficie celular con ligandos tal como fibronectina y colágeno con un anticuerpo anti-endosialina.
MX2009010701A 2007-04-05 2008-04-04 Metodos para inhibir la union de endosialina a ligandos. MX2009010701A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91036207P 2007-04-05 2007-04-05
US98002607P 2007-10-15 2007-10-15
PCT/US2008/059374 WO2008124570A1 (en) 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands

Publications (1)

Publication Number Publication Date
MX2009010701A true MX2009010701A (es) 2010-01-20

Family

ID=39714208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010701A MX2009010701A (es) 2007-04-05 2008-04-04 Metodos para inhibir la union de endosialina a ligandos.

Country Status (20)

Country Link
US (4) US7807382B2 (es)
EP (2) EP2620451B1 (es)
JP (2) JP5825784B2 (es)
KR (1) KR101529334B1 (es)
CN (1) CN101918446B (es)
AU (1) AU2008237296B2 (es)
BR (1) BRPI0809665B8 (es)
CA (1) CA2682726C (es)
CY (2) CY1115370T1 (es)
DK (2) DK2137217T3 (es)
ES (2) ES2452929T3 (es)
HR (2) HRP20140266T1 (es)
HU (1) HUE031269T2 (es)
LT (1) LT2620451T (es)
MX (1) MX2009010701A (es)
PL (2) PL2137217T3 (es)
PT (2) PT2137217E (es)
RS (2) RS55447B1 (es)
SI (2) SI2137217T1 (es)
WO (1) WO2008124570A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1871809A2 (en) * 2005-04-22 2008-01-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
CA2682726C (en) * 2007-04-05 2017-05-09 Morphotek, Inc. Methods for inhibiting the binding of endosialin to ligands
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
WO2010118203A2 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
JP2013543379A (ja) 2010-09-29 2013-12-05 モルフォテック， インコーポレイテッド 操作されたヒトエンドシアリン発現齧歯動物
WO2013148250A1 (en) 2012-03-30 2013-10-03 Morphotek, Inc. Tem-1 diagnostic antibodies
US9783610B2 (en) * 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
WO2014164544A1 (en) 2013-03-09 2014-10-09 Baylor College Of Medicine Vascular-targeted t-cell therapy
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
CN111026023A (zh) * 2020-01-12 2020-04-17 安徽楚江科技新材料股份有限公司 基于s7-400控制系统的铜带轧机PLC组态方法
CN116790744B (zh) * 2023-06-30 2024-04-26 浙江大学 一种缺血性心脏病晚期纤维化干预靶点及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) * 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
EP0686260B1 (en) * 1993-02-05 2003-07-09 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
DE69535002T2 (de) * 1994-03-08 2006-12-07 Memorial Sloan-Kettering Cancer Center Rekombinante humanisierte antikörper gegen fb5
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6146894A (en) * 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
WO2000013575A1 (en) 1998-09-09 2000-03-16 U.S. Army Institute Of Surgical Research Method for monitoring arterial oxygen saturation
US20040048254A1 (en) 2000-03-15 2004-03-11 Alexander Olek Diagnosis of diseases associated with tumor supressor genes and oncogenes
JP2004527210A (ja) 2000-08-02 2004-09-09 ザ ジョンズ ホプキンス ユニバーシティー 内皮細胞発現パターンの評価法
WO2002054856A1 (en) 2001-01-15 2002-07-18 Morphotek Inc. Chemical inhibitors of mismatch repair
US20040043928A1 (en) 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040014058A1 (en) 2001-10-05 2004-01-22 Alsobrook John P. Novel human proteins, polynucleotides encoding them and methods of using the same
EP2236614A3 (en) 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
EP2264073A1 (en) * 2003-03-04 2010-12-22 Kirin Beer Kabushiki Kaisha Endothelial cell specific antibodies and uses thereof
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2006029045A2 (en) 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
US20070292354A1 (en) 2004-09-23 2007-12-20 Guerbet Contrast Agents Encapsulating Systems for Cest Imaging
EP1819736B1 (en) * 2004-12-03 2010-08-04 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
EP1871809A2 (en) 2005-04-22 2008-01-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
US7315372B1 (en) * 2005-09-29 2008-01-01 The United States Of America As Represented By The Secretary Of The Navy Instrument using near-field intensity correlation measurements for characterizing scattering of light by suspensions
DE102005050933A1 (de) 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
EP1960552A2 (en) 2005-12-16 2008-08-27 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
WO2008006517A2 (en) 2006-07-13 2008-01-17 Siemens Healthcare Diagnostics Gmbh Prediction of breast cancer response to taxane-based chemotherapy
EP2049713A4 (en) 2006-07-21 2010-06-16 Univ Alberta tissue rejection
EP2543739B1 (en) 2006-08-11 2015-07-22 Johns Hopkins University Consensus coding sequences of human colorectal cancers
US20080300170A1 (en) 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
WO2008063479A2 (en) 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
US20110119776A1 (en) 2007-02-05 2011-05-19 Wong Kwok-Kin Methods of diagnosing and prognosing lung cancer
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
CA2682726C (en) * 2007-04-05 2017-05-09 Morphotek, Inc. Methods for inhibiting the binding of endosialin to ligands
EP1986010A1 (en) 2007-04-05 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and tools for discriminating colorectal adenomas and adenocarcinomas
CA2733672C (en) 2007-08-16 2018-09-11 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
KR101810799B1 (ko) 2008-02-01 2017-12-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
CA2715774A1 (en) 2008-02-19 2009-08-27 Oncomethylome Sciences Sa Detection and prognosis of lung cancer
WO2009120877A2 (en) 2008-03-26 2009-10-01 The Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US20100136584A1 (en) 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20110256560A1 (en) 2008-10-20 2011-10-20 University Health Network Methods and compositions for the detection of ovarian cancer
CA2749601C (en) 2009-01-14 2020-07-21 Stephen M. Hewitt Ratio based biomarkers and methods of use thereof
WO2010118203A2 (en) 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules

Also Published As

Publication number Publication date
RS55447B1 (sr) 2017-04-28
BRPI0809665A2 (en) 2018-12-04
CA2682726A1 (en) 2008-10-16
HRP20140266T1 (hr) 2014-04-25
AU2008237296A1 (en) 2008-10-16
HUE031269T2 (en) 2017-06-28
ES2452929T3 (es) 2014-04-03
EP2620451B1 (en) 2016-09-14
HRP20161715T1 (hr) 2017-02-10
US20080248034A1 (en) 2008-10-09
CY1115370T1 (el) 2017-01-04
PL2137217T3 (pl) 2014-08-29
US10053509B2 (en) 2018-08-21
EP2137217A1 (en) 2009-12-30
DK2620451T3 (da) 2017-01-02
RS53362B (sr) 2014-10-31
PT2620451T (pt) 2016-12-20
SI2620451T1 (sl) 2017-01-31
LT2620451T (lt) 2017-01-10
WO2008124570A8 (en) 2008-11-27
US7807382B2 (en) 2010-10-05
JP5825784B2 (ja) 2015-12-02
DK2137217T3 (en) 2014-03-17
EP2620451A1 (en) 2013-07-31
PL2620451T3 (pl) 2017-06-30
SI2137217T1 (sl) 2014-07-31
US8895000B2 (en) 2014-11-25
ES2606906T3 (es) 2017-03-28
PT2137217E (pt) 2014-03-20
JP2013150618A (ja) 2013-08-08
CY1118592T1 (el) 2017-07-12
BRPI0809665B8 (pt) 2021-05-25
AU2008237296B2 (en) 2013-07-04
US20170029509A1 (en) 2017-02-02
JP2010523592A (ja) 2010-07-15
WO2008124570A1 (en) 2008-10-16
US20110033455A1 (en) 2011-02-10
US20150079104A1 (en) 2015-03-19
CN101918446B (zh) 2014-06-18
KR101529334B1 (ko) 2015-06-16
BRPI0809665B1 (pt) 2021-03-23
KR20100016221A (ko) 2010-02-12
CA2682726C (en) 2017-05-09
US9505842B2 (en) 2016-11-29
CN101918446A (zh) 2010-12-15
EP2137217B1 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
MX2009010701A (es) Metodos para inhibir la union de endosialina a ligandos.
TN2010000169A1 (en) Molecules and methods for modulating complement component
NZ700891A (en) 4-1bb binding molecules
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
IL248726A0 (en) Systems and methods for defining a semantic concept and synthesis of a semantic concept relation while utilizing existing domain definitions
MX2012010853A (es) Anticuerpos anti-lrp6.
SG10201508789TA (en) Prevention of adverse effects caused by cd3 specific binding domains
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
PH12013502230A1 (en) Multispecific antibodies
EP2347038A4 (en) METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
MX342851B (es) Metodos y materiales para sintesis enzimatica de compuestos mogrosido.
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
TN2009000182A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
MX2010010209A (es) 4-hidroxipirimidina-5-carboxamidas sustituidas.
IL211937A0 (en) Methods for purification of single domain antigen binding molecules
ATE543910T1 (de) Verfahren und materialien zur herstellung von simvastatin und verwandten verbindungen
IL212383A0 (en) Muc-1 cytoplasmic domain peptides as inhibitors of cancer
AU2012270029A8 (en) Compositions and methods for modulating a kinase
SG178881A1 (en) Antibodies against cdcp1 for the treatment of cancer
WO2010118203A3 (en) Endosialin binding molecules
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
MX2011013878A (es) 4-hidroxipirimidina-5-carboxamidas sustituidas.
MX2012002013A (es) Moduladores de activador del factor de crecimiento de hepatocitos.
MX2011013879A (es) 4-hidroxipirimidina-5-carboxamidas sustituidas.

Legal Events

Date Code Title Description
FG Grant or registration